This Antibody was verified by Relative expression to ensure that the antibody binds to the antigen stated. View Details
Western blot analysis of MA1-153 detects ~130-160 kDa and a 210-250 kDa protein in K562 cells. In addition to BCR-ABL, BCR and ABL are also expressed in these cells and full length BCR is also detected by the antibody. For detection purposes, non-reducing conditions resulted in enhanced detection of BCR-ABL.
A reciprocal translocation between chromosomes 22 and 9 produces the BCR-ABL fusion oncoprotein, which is found in patients with chronic myelogenous leukemia (CML). Although there are various versions, p210 is the most commonly found BCR-ABL form. The fusion to BCR, results in deregulated/constitutively active tyrosine kinase activity of BCR-ABL which is sufficient of oncogenic transformation of myeloid cells. Inhibition of BCR-ABL oncogenic activity by the ABL-kinase inhibitor STI-571 (also known as gleevec, imatinib) became the first and best example for successful targeted therapy of cancer, and specifically CML. In recent years, several mutations (such as the T351I mutation) were found in CML patients that resulted in STI-571 resistance and the need for additional drug development.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: BCR/FGFR1 chimera protein; BCR1; breakpoint cluster region; breakpoint cluster region homolog; Breakpoint cluster region protein; FGFR1/BCR chimera protein; PHL; Renal carcinoma antigen NY-REN-26
Gene Aliases: 5133400C09Rik; AI561783; AI853148; ALL; BCR; BCR1; CML; D22S11; D22S662; Kiaa3017; mKIAA3017; PHL